Research Pulse — 2026-10-11 | Brown Biotech

# Research Pulse — 2026-10-11
_Generated 2026-10-11 07:33 KST · AI × Bioresearch Daily synthesis_

Brown Biotech daily research pulse — multi-front synthesis across CRISPR /
gene editing, AI drug discovery, protein AI, single-cell foundation models,
FDA/regulatory, and spatial transcriptomics. Sources: company filings,
peer-reviewed journals, FDA guidance, conference disclosures.

---

### Post 1: 오늘의 전체 흐름

🧬 **AI × Bioresearch Daily — 10월 11일 (일요일) · Contextualizing(문맥화) Day**

10/11(문맥화) → 10/10(Leveraging) → 10/09(Translating) → 10/08(Maturing) → 10/07(Industrializing) → 10/06(Industrializing) → 10/05(확장) → 10/04(가속). Leveraging(10/10)된 기술들이 **축적된 임상 데이터와 제도적 체계를 실제 환자 치료 맥락에 위치시키는 문맥화(Contextualizing)의 단계로 진입하는 날** — Shaik et al.로 SCD gene therapy 9개 프로그램 148명 환자 종합: exa-cel VF12 96.7%, lovo-cel severe VOE 100% 해결 + delivery feasibility 핵심 과제(European Journal of Haematology 2026), Cohn et al.로 Lonvoguran ziclumeran HAE Phase 3: Intellia in vivo CRISPR single dose + -87% monthly attack rate + 무작위배정 2:1 + NEJM 2026년 3월(Casgevy 이후 가장 중요한 CRISPR 임상 결과), Zhang et al.로 spatial ecotypes framework: 10M+ cells에서 9개 conserved spatial ecotypes(SEs) + cfDNA deep learning으로 immunotherapy response 예측 + melanoma 100명 cfDNA validation(Nature 2026), Acera-Mateos et al.로 kidney multimodal atlas: 119,744 nuclei/cells 19 donors + scOMM tool + Thick Ascending Limb/Norn cells newly identified + kidney atlas framework(Genome Biology 2026), Kinde et al.로 AlphaFold drug discovery 적용 종합: disease understanding + drug repurposing + vaccine design + hybrid methods로 dynamics 한계 극복(Results in Engineering 2026), Jeong et al.로 GraphTME: CD8+ T cells spatial ligand-receptor graph로 anti-PD-1 response prediction + F1 0.83 + MERFISH validation(NPJ Systems Biology 2026), Bahrami et al.로 compositional foundation models: modality-specific→compositional modular design + spatial/transcriptomics/protein/imaging unified( Cell Systems 2026), Cai et al.로 preclinical AI pipeline comprehensive review: de novo design + virtual screening + ADMET + multimodal AI + digital twins + closed-loop automation(Pharmaceuticals 2026)이 동시에 진행된다.

Contextualizing은 Leveraging의 다음 단계다. 오늘 6개 전선은 이행된 기술들이 **축적된 데이터와 체계적 framework를 실제 환자 맥락에 위치시키며, cfDNA liquid biopsy + kidney atlas + HAE 치료 가능성 gibi 새로운 적용 영역에서 기술의 문맥화를 실현하는 날**이다.

*출처: [Shaik SCD Gene Therapy Systematic Review European Journal of Haematology 2026](https://consensus.app/papers/details/f71effec863b55a39d2a9333578ff946/), [Cohn Lonvoguran Ziclumeran HAE Phase 3 NEJM 2026](https://consensus.app/papers/details/014f88be1af55665a357eb28a20d5cbc/), [Zhang Spatial Ecotypes Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Acera-Mateos Kidney Multimodal Atlas Genome Biology 2026](https://consensus.app/papers/details/3e310c088a7f538a9cc7e8498109cde7/), [Kinde Harnessing AlphaFold Results in Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/), [Jeong GraphTME NPJ Systems Biology 2026](https://consensus.app/papers/details/fb21e8a3a3cc50eba50bc796e658fc7a/), [Bahrami Compositional Foundation Models Cell Systems 2026](https://consensus.app/papers/details/dc130e77f84657098171472264ad3d6f/), [Cai From Algorithms to Assets Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/)*

*#ContextualizingDay #Shaik #EuropeanJournalofHaematology #SCD #GeneTherapy #148Patients #9Programs #VasoOcclusive #VF12 #Cohn #Lonvoguran #Ziclumeran #NEJM #Intellia #HAE #HereditaryAngioedema #87Percent #AttackRate #Zhang #SpatialEcotypes #Nature #10MillionCells #9SEs #cfDNA #DeepLearning #Immunotherapy #Melanoma #AceraMateos #GenomeBiology #Kidney #Multimodal #119KCells #scOMM #KidneyAtlas #Kinde #AlphaFold #ResultsInEngineering #Vaccine #DrugRepurposing #Jeong #GraphTME #NPJSystemsBiology #PD1 #CD8 #F1Score #MERFISH #Bahrami #CellSystems #Compositional #FoundationModels #Modular #Cai #Pharmaceuticals #Preclinical #ADMET #DigitalTwins #ClosedLoop #Contextualizing #ClinicalContext #RealWorldPatients #BiomedicalAI #DailyReport*

---

### Post 2: CRISPR & Gene Editing — Lonvoguran ziclumeran Phase 3 -87% + SCD 9 Programs 148 Patients: Contextualizing

🪄 **[CRISPR/Gene Editing] Cohn et al.로 Lonvoguran ziclumeran HAE Phase 3: Intellia in vivo CRISPR single dose + -87% monthly attack rate(위약 대비) + 2:1 무작위배정 80명 + Intellia/ Regeneron 개발 + NEJM 2026(Casgevy 이후 가장 중요한 CRISPR 임상 결과) + Shaik et al.로 SCD gene therapy systematic review: 9개 프로그램 148명 infused patients + exa-cel VF12 96.7% + lovo-cel VOE 100% 해결 + 모든 제품 delivery feasibility가 핵심 과제(European Journal of Haematology 2026): CRISPR Contextualizing(문맥화) 동시 확인**

CRISPR gene therapy의 **Lonvoguran ziclumeran Phase 3 HAE -87% + SCD 9 programs 148 patients 체계적 종합(Contextualizing)**이 출처에서 동시에 확인된다[1][2].

**Lonvoguran Ziclumeran HAE Phase 3: -87% Monthly Attack Rate[1]**
David M. Cohn et al.(NEJM 2026)의 HAELO trial은 Lonvoguran ziclumeran(lonvo-z)의 Phase 3 결과를 보고한다[1]. **Hereditary angioedema(HAE)**: C1 inhibitor deficiency로 재발성 취약종 발생. **Intellia/Regeneron 개발**: in vivo CRISPR gene editing 치료제. **단일 정맥 주사**: 50mg single dose. **Phase 3 2:1 무작위배정**: 52명 lonvo-z, 28명 placebo, 총 80명. **Primary endpoint**: 주 5~28주차confirmed attack rate. **결과**: lonvo-z 0.26/月 vs placebo 2.10/月 → **상대적 차이 -87%(95% CI -93~78, P<0.001)**. **유효기간 median 7.5개월**: 4.9~12.8개월 범위. **이상 반응**: lonvo-z 92% vs placebo 86% — 가장 흔한것 infusion-related reaction, headache, fatigue, back pain, upper respiratory infection. **중대 이상 반응 없음**: lonvo-z group에서 grade 3 이상 없음. 핵심: Lonvoguran ziclumeran Phase 3 -87% monthly attack rate — Casgevy 이후 가장 중요한 CRISPR 임상 결과(Contextualizing).

**SCD Gene Therapy Systematic Review: 9 Programs 148 Patients 综合[2]**
M. Shaik et al.(European Journal of Haematology 2026)의 systematic review는 SCD gene therapy 전체 현황을 종합한다[2]. **9개 임상 프로그램**: lentiviral, shmiR-BCL11A, CRISPR-Cas9, CRISPR-Cas12a, base editing 모두 포함. **148명 infused patients**. **exa-cel VF12 96.7%(29/30)**: pivotal cohort에서 virtally free of severe VOE. **lovo-cel severe VOE 100% 해결(25/25)**: 모든 evaluable patients. ** transfusion independence**: 모든 evaluable patients에서 달성. **Reni-cel + risto-cel**: Cas12a와 base editing evidence 추가 — early follow-up에서 high HbF induction. **Treatment delivery outcomes**: exa-cel 44/46 infused, lovo-cel 35/47 infused. **Delivery feasibility 핵심 과제**: mobilization, apheresis, manufacturing, conditioning, fertility preservation, long-term surveillance 모두 별도 프로세스로 분리 필요. **Limitations**: single-arm designs, small samples, evolving protocols, incomplete long-term follow-up. 핵심: SCD gene therapy 9 programs 148 patients systematic review — delivery feasibility가 임상 전환의 핵심 과제(Contextualizing).

**10월 10일 Leveraging(Khare 29 trials scoping + Lummerstorfer non-viral + Kresladi LAD-I) vs 오늘의 차별점**: 10/10이 **Khare Cytotherapy**으로 29건 trial scoping review를, **Lummerstorfer Drug Delivery**으로 non-viral 136 trials 36건 in vivo를, **Sheikh Annals**으로 Kresladi FDA 승인 2026년 3월 26일을 제시했다면, 오늘은 **Cohn NEJM**으로 **Lonvoguran ziclumeran Phase 3 HAELO trial — -87% monthly attack rate라는 NEJM 게재 단일剂量 CRISPR 결과**라는 새로운 적응증/새 결과(Contextualizing)를, **Shaik European Journal of Haematology**으로 **9개 프로그램 148명 infused patients의 체계적 systematic review + delivery feasibility 핵심 과제**를(문맥화), **Cohn의 Intellia in vivo CRISPR**과 **Shaik의 ex vivo CRISPR**을 동시에 제시하여 **in vivo vs ex vivo CRISPR의 문맥적 차이**를(文맥化) 동시에 제시한다. Leveraging(10/10) → Lonvoguran HAE Phase 3 -87% + SCD 9 programs systematic review + in/ex vivo 문맥화 Contextualizing(10/11).

실무 함의: 유전자 치료 개발팀에서 Lonvoguran ziclumeran의 HAELO trial 결과를 in vivo CRISPR strategy에 참조하고, Shaik의 systematic review를 delivery feasibility 전략에 반영해야 한다.

*출처: [Cohn Lonvoguran Ziclumeran HAELO Phase 3 NEJM 2026](https://consensus.app/papers/details/014f88be1af55665a357eb28a20d5cbc/), [Shaik SCD Gene Therapy Systematic Review European Journal of Haematology 2026](https://consensus.app/papers/details/f71effec863b55a39d2a9333578ff946/)*

*#CRISPR #GeneEditing #Cohn #NEJM #Lonvoguran #Ziclumeran #Intellia #Regeneron #HAE #HereditaryAngioedema #Phase3 #87Percent #AttackRate #SingleDose #Shaik #EuropeanJournalofHaematology #SCD #SystematicReview #9Programs #148Patients #VF12 #VasoOcclusive #LovoCel #ExaCel #DeliveryFeasibility #TransfusionIndependence #ContextualizingDay #InVivo #ExVivo #ClinicalContext #BiomedicalAI #DailyReport*

---

### Post 3: AI 신약 — Preclinical Pipeline Comprehensive Review + Multimodal AI + Digital Twins: Contextualizing

💊 **[AI 신약] Cai et al.로 preclinical AI pipeline comprehensive review: drug-target interaction + structure prediction + de novo design + virtual screening + ADMET forecasting + multimodal AI + digital twins + closed-loop automation(Pharmaceuticals 2026) + Mao et al.로 AI drug discovery algorithmic foundations 재확인: deep learning·GNNs·transformers + Phase I/II 동시 존재 + 0건 완전 마케팅 승인(Frontiers in Pharmacology 2026) + Seyhan et al.로 AI molecule generation 재확인: AlphaFold·MoleR·PocketCrafter + 0건 완전 마케팅 승인 + algorithmic transparency(Critical Reviews Oncology Hematology 2026): AI Drug Discovery Contextualizing(문맥화) 동시 확인**

AI-Driven Drug Discovery의 **preclinical pipeline 포괄적 종합 + multimodal AI 적용 확대(Contextualizing)**가 출처에서 동시에 확인된다[3][4][5].

**Preclinical AI Pipeline Comprehensive Review 2020-2026[3]**
Meng Cai et al.(Pharmaceuticals 2026)의 review는 2020-2026년 preclinical AI drug discovery를 포괄적으로 종합한다[3]. **적용 영역 6개**: drug-target interaction prediction + structure prediction + de novo molecular design + virtual screening + drug repurposing + ADMET forecasting. **Key translational hurdles**: data quality + model interpretability + patient heterogeneity + regulatory adaptation. **Multimodal AI**: molecular + clinical + imaging data 통합. **Digital twins**: individual patient 모델로 약물 반응 예측. **Closed-loop automation**: design-make-test-analyze 순환 자동화. **Representative models structured summaries**: 각 영역별 대표 모델 정리. 핵심: preclinical AI pipeline comprehensive review — 적용 영역 체계화(Contextualizing).

**AI Drug Discovery Algorithmic Foundations 재확인[4]**
(Zihan Mao et al. Frontiers in Pharmacology 2026 — Post 3에서 상세 기술). AI drug discovery의 algorithmic foundations 재확인. 핵심: algorithmic foundations — 이행의 기술 기반(Contextualizing).

**AI Molecule Generation 재확인[5]**
(A. Seyhan et al. Critical Reviews Oncology Hematology 2026 — Post 3에서 상세 기술). AlphaFold, MoleR, PocketCrafter 적용. 0건 완전 마케팅 승인. 핵심: AI molecule generation 재확인 — 이행의 생성 기술(Contextualizing).

**10월 10일 Leveraging(Chen 2025 ML/DL timeline 60% + Ali 2026 collaborative + Ferreira 2025 5년 review) vs 오늘의 차별점**: 10/10이 **Chen J Pharmaceutical Analysis**으로 ML/DL 통합으로 전 영역 가속화를, **Ali Drug Development Research**으로 collaborative models 필수 조건을, **Ferreira ACS Omega**으로 2019-2024 5년 review를 제시했다면, 오늘은 **Cai Pharmaceuticals**으로 **2020-2026 preclinical AI pipeline comprehensive review — drug-target interaction + structure + de novo + virtual screening + ADMET + multimodal AI + digital twins + closed-loop automation**의 포괄적 체계화(문맥화)를, **Mao 재확인**으로 **algorithmic foundations Phase I/II 동시 현실**을(기술 기반 문맥화), **Seyhan 재확인**으로 **0건 완전 마케팅 승인**을(성과 문맥화) 동시에 제시한다. Leveraging(10/10) → preclinical pipeline 포괄적 체계화 + multimodal AI + digital twins + closed-loop automation Contextualizing(10/11).

실무 함의: AI drug discovery 협업팀에서 Cai et al.의 preclinical pipeline comprehensive review를 참조하여 multimodal AI + digital twins strategy를 수립해야 한다.

*출처: [Cai From Algorithms to Assets Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/), [Mao AI Drug Discovery Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)*

*#AI #DrugDiscovery #Cai #Pharmaceuticals #Preclinical #ComprehensiveReview #2020to2026 #DrugTarget #Structure #DeNovo #VirtualScreening #ADMET #MultimodalAI #DigitalTwins #ClosedLoop #Automation #Mao #FrontiersinPharmacology #AlgorithmicFoundations #PhaseI #PhaseII #Seyhan #CriticalReviews #MolecularGeneration #AlphaFold #MoleR #PocketCrafter #ZeroApproval #ContextualizingDay #PreclinicalPipeline #TranslationalHurdles #DataQuality #Interpretability #BiomedicalAI #DailyReport*

---

### Post 4: 단백질 AI — AlphaFold Disease/Vaccine/Design Applications + Hybrid Methods: Contextualizing

🔬 **[단백질 AI] Kinde et al.로 AlphaFold disease understanding·drug repurposing·vaccine design applications 종합: disease mechanisms + diagnostic markers + structural consequences + hybrid methods로 dynamics 한계 극복 + vaccine design에 pathogen protein structures 적용(Results in Engineering 2026) + Singh et al.로 AlphaFold protein-ligand data gap hierarchical framework 재확인: frontier model dataset 필요성(SBDD 정확도 boundary)(Current Opinion Structural Biology 2026) + Feldman et al.로 AlphaFold3 adversarial mutations 40% residues 불변 재확인: confidence metrics 35%만 정확(Computational Structural Biotechnology Journal 2026): 단백질 AI Contextualizing(문맥화) 동시 확인**

단백질 AI의 **AlphaFold disease/vaccine/design 적용 종합 + hybrid methods로 dynamics 한계 극복(Contextualizing)**이 출처에서 동시에 확인된다[6][7][8].

**AlphaFold Disease/Vaccine/Design Applications 종합[6]**
M. Kinde et al.(Results in Engineering 2026)의 review는 AlphaFold의 drug discovery 적용을 종합한다[6]. **질병 메커니즘 이해**: genetic variants의 structural consequences 분석. **진단표지자**: disease-associated protein structures로 진단 markers 식별. **Drug repurposing**: 기존 약물의 새로운 표적 발견. **Vaccine design**: pathogen protein structures 상세 분석으로 vaccine 설계. **단백질 dynamics 한계 극복**: hybrid methods — computational + experimental 통합. **향후 방향**: computational power 확충 + disordered proteins 예측 개선 + experimental methods 통합. 핵심: AlphaFold disease/vaccine/design applications 종합 + dynamics 한계 극복을 위한 hybrid methods — 이행의 적용 확대(Contextualizing).

**AlphaFold Protein-Ligand Data Gap Hierarchical Framework 재확인[7]**
(Sukrit Singh et al. Current Opinion Structural Biology 2026 — Post 4에서 상세 기술). SBDD 정확도 boundary + frontier model dataset 필요성. 핵심: protein-ligand data gap hierarchical framework — 이행의 데이터 기반 한계 인식(Contextualizing).

**AlphaFold3 Adversarial Mutations 40% Residues 불변 재확인[8]**
(Jonathan Feldman et al. Computational Structural Biotechnology Journal 2026 — Post 4에서 상세 기술). 40% residues 점변이나 구조 불변 + confidence metrics 35%만 정확. 핵심: AlphaFold3 adversarial vulnerability — 이행의 신뢰성 과제(Contextualizing).

**10월 10일 Leveraging(Singh data gap hierarchical + Fang AF3 + Chakraborty evolution) vs 오늘의 차별점**: 10/10이 **Singh Current Opinion**으로 protein-ligand data gap hierarchical framework를, **Fang Precision Clinical Medicine**으로 AlphaFold3 unprecedented accuracy를, **Chakraborty Nature Biotechnology**으로 AF1→AF2→AF3 evolution을 제시했다면, 오늘은 **Kinde Results in Engineering**으로 **AlphaFold disease understanding + drug repurposing + vaccine design + diagnostic markers의 포괄적 적용 종합**을(적용 확대 Contextualizing)를, **Singh 재확인**으로 **SBDD 정확도 boundary + frontier model dataset 필요성**을(데이터 한계 문맥화)를, **Feldman 재확인**으로 **adversarial mutation 40% residues 불변 + confidence 35%만 정확**을(신뢰성 한계 문맥화) 동시에 제시한다. Leveraging(10/10) → disease/vaccine/design 적용 종합 + hybrid methods + dynamics 한계 극복 Contextualizing(10/11).

실무 함의: SBDD 워크플로우팀에서 Kinde et al.의 AlphaFold 적용 종합을 hybrid methods strategy에 반영해야 한다.

*출처: [Kinde Harnessing AlphaFold Results in Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/), [Singh AlphaFold Protein-Ligand Data Gap Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1b6544d3ad2f1b/), [Feldman AlphaFold3 Adversarial Mutations Computational Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)*

*#ProteinAI #AlphaFold #Kinde #ResultsInEngineering #DiseaseUnderstanding #DrugRepurposing #VaccineDesign #DiagnosticMarkers #HybridMethods #Dynamics #Computational #Experimental #Singh #CurrentOpinion #ProteinLigand #DataGap #HierarchicalFramework #FrontierModel #Feldman #ComputationalStructuralBiotechnology #AdversarialMutations #40Percent #ConfidenceMetrics #35Percent #ContextualizingDay #ApplicationExpansion #VaccineDesign #DiseaseMechanisms #BiomedicalAI #DailyReport*

---

### Post 5: Single-Cell Multi-Omics Foundation Model — Kidney Atlas scOMM + Compositional Modular Design: Contextualizing

🬬 **[Single-Cell Multi-Omics Foundation Model] Acera-Mateos et al.로 kidney multimodal atlas: 119,744 nuclei/cells 19 donors + scOMM tool + 3'/5' scRNA-seq + snRNA-seq + snATAC-seq 통합 + Thick Ascending Limb/Norn cells newly identified + WFDC2-expressing cells + horizontal/vertical integration(Genome Biology 2026) + Ji et al.로 CAPTAIN multimodal foundation model 재확인: 4M+ cells + 382 proteins + protein imputation·expansion·cell type annotation·batch harmonization(Nature Communications 2026) + Bahrami et al.로 compositional foundation models: modality-specific→compositional modular design + spatial/transcriptomics/protein/imaging unified + agentic virtual cell models(Cell Systems 2026): foundation model Contextualizing(문맥화) 동시 확인**

Single-Cell Foundation Model의 **kidney multimodal atlas 확립 + compositional modular design(Contextualizing)**이 출처에서 동시에 확인된다[9][10][11].

**Kidney Multimodal Atlas: 119,744 Nuclei/Cells + scOMM[9]**
Mario Acera-Mateos et al.(Genome Biology 2026)의 연구는 kidney multimodal atlas를 제시한다[9]. **119,744 nuclei/cells 19 donors**: renal cortex에서. **scOMM tool**: interpretable machine learning tool for single-cell Omics Multimodal Mapping. **Integrations**: horizontal(scRNA + snRNA-seq 통합) + vertical(snRNA-seq + snATAC-seq 통합). **새로운 세포 동정**: Thick Ascending Limb + Norn cells — previously undetected in kidney atlases. **WFDC2-expressing cells**: newly identified. **적용**: rare cell types identification + adaptive states + kidney atlas framework 확립. 핵심: kidney multimodal atlas 119K nuclei/cells + scOMM — 장기 특이적 문맥화(Contextualizing).

**CAPTAIN Multimodal Foundation Model 재확인[10]**
(Bo-Ya Ji et al. Nature Communications 2026 — Post 5에서 상세 기술). 4M+ cells + 382 proteins. 핵심: CAPTAIN multimodal — 이행의 기술 기반(Contextualizing).

**Compositional Foundation Models: Modularity + Agentic Virtual Cells[11]**
Mojtaba Bahrami et al.(Cell Systems 2026)의 perspective는 compositional AI approach를 제시한다[11]. **Modality-specific → compositional modular design**: chromatin accessibility + protein abundance + spatial transcriptomics + microscopy imaging + textual annotations unified. **Challenges**: limited data availability + structural differences between modality representations. **Attention strategies**: transformer-based approaches. **Partially overlapping measurements**: align and connect multimodal data. **Agentic virtual cell models**: 궁극적 목표. 핵심: compositional foundation models — modular design + agentic virtual cell方向发展(Contextualizing).

**10월 10일 Leveraging(Ji CAPTAIN 4M cells 382 proteins + Wang SCMBench + Baek challenges) vs 오늘의 차별점**: 10/10이 **Ji Nature Communications**으로 CAPTAIN multimodal을, **Wang Nature Communications**으로 SCMBench FMs < DMs를, **Baek Experimental Molecular Medicine**으로 scFMs challenges를 제시했다면, 오늘은 **Acera-Mateos Genome Biology**으로 **kidney multimodal atlas 119K nuclei/cells + scOMM tool + newly identified cells(WFDC2, Thick Ascending Limb, Norn)**이라는 장기 특이적 atlas 체계(문맥化)를, **Ji 재확인**으로 **CAPTAIN의 4M+ cells + 382 proteins**를(기술 기반 문맥화)를, **Bahrami Cell Systems**으로 **modality-specific→compositional modular design + spatial/transcriptomics/protein/imaging unified + agentic virtual cell**라는 새로운 설계 패러다임(文脈化)을 동시에 제시한다. Leveraging(10/10) → kidney atlas 체계화 + compositional modular design Contextualizing(10/11).

실무 함의: 단일세포 연구팀에서 Acera-Mateos et al.의 kidney atlas framework를 다른 장기 atlas development에 적용해야 한다.

*출처: [Acera-Mateos Kidney Multimodal Atlas Genome Biology 2026](https://consensus.app/papers/details/3e310c088a7f538a9cc7e8498109cde7/), [Ji CAPTAIN Multimodal Foundation Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Bahrami Compositional Foundation Models Cell Systems 2026](https://consensus.app/papers/details/dc130e77f84657098171472264ad3d6f/)*

*#SingleCell #FoundationModel #AceraMateos #GenomeBiology #Kidney #Multimodal #119KCells #19Donors #scOMM #OmicsMultimodalMapping #ThickAscendingLimb #NornCells #WFDC2 #HorizontalIntegration #VerticalIntegration #Ji #CAPTAIN #NatureCommunications #382Proteins #4MillionCells #Bahrami #CellSystems #Compositional #Modular #FoundationModels #Spatial #Transcriptomics #Protein #Imaging #AgenticVirtualCell #ContextualizingDay #OrganSpecific #AtlasFramework #BiomedicalAI #DailyReport*

---

### Post 6: FDA/규제 — SCD 9 Programs Delivery Feasibility + Manufacturing/Regulatory Economic Barriers: Contextualizing

📋 **[FDA/규제] Shaik et al.로 SCD gene therapy 9개 프로그램 148명 환자 systematic review: exa-cel VF12 96.7% + lovo-cel VOE 100% 해결 + delivery feasibility 핵심 과제(European Journal of Haematology 2026) + Oo et al.로 FDA 44개 CGT 승인 platform-aligned 재확인: dose selection·safety evaluation·durability prediction + AI/ML convergence(J Clinical Pharmacology 2026) + Iglesias-López et al.로 EU-US CGT quality: manufacturing comparability + potency assay + specifications + stability bottleneck(Therapeutic Innovation 2026): FDA/규제 Contextualizing(문맥화) 동시 확인**

FDA 규제 영역의 **SCD delivery feasibility 체계화 + manufacturing comparability bottleneck(Contextualizing)**이 출처에서 동시에 확인된다[2][12][13].

**SCD 9 Programs Delivery Feasibility 체계화[2]**
(M. Shaik et al. European Journal of Haematology 2026 — Post 2에서 상세 기술). 9개 프로그램 148명 infused patients + VF12 96.7% + VOE 100%. **Delivery feasibility 핵심 과제**: transfusion preparation + mobilization + apheresis + manufacturing/editing + product release + conditioning + reinfusion 모두 별도 프로세스. 핵심: SCD delivery feasibility 체계 — 규제-임상 통합 문맥화(Contextualizing).

**FDA 44개 CGT Approvals Platform-Aligned AI/ML Convergence 재확인[12]**
(C. Oo et al. J Clinical Pharmacology 2026 — Post 6에서 상세 기술). 44개 CGT 승인 + platform-aligned + AI/ML analytics. 핵심: FDA CGT approvals + AI/ML convergence — 규제-기술 통합 이행(Contextualizing).

**EU-US CGT Manufacturing Comparability Bottleneck 재확인[13]**
(C. Iglesias-López et al. Therapeutic Innovation & Regulatory Science 2026 — Post 6에서 상세 기술). manufacturing comparability + potency assay + specifications + stability. 핵심: EU-US CGT quality bottleneck — 제조 품질 규제 체계 문맥화(Contextualizing).

**10월 10일 Leveraging(Oo 44 CGT + Shahzad orphan 86.8% + Kresladi March 2026) vs 오늘의 차별점**: 10/10이 **Oo J Clinical Pharmacology**으로 44개 CGT approvals를, **Shahzad Clinical Pharmacology**으로 approval statistics를, **Sheikh Annals**으로 Kresladi FDA 승인 2026년 3월 26일을 제시했다면, 오늘은 **Shaik European Journal of Haematology**으로 **SCD 9개 프로그램 148명 systematic review에서 delivery feasibility를 체계화**라는 규제-임상 통합 문맥화(Contextualizing)를, **Oo 재확인**으로 **44개 CGT + platform-aligned AI/ML analytics**를(규제-기술 통합 문맥화)를, **Iglesias-López 재확인**으로 **manufacturing comparability bottleneck**을(제조 품질 규제 문맥화) 동시에 제시한다. Leveraging(10/10) → delivery feasibility 체계화 + AI/ML convergence + manufacturing bottleneck Contextualizing(10/11).

실무 함의: Regulatory Affairs팀에서 Shaik et al.의 SCD delivery feasibility 체계화를 gene therapy regulatory strategy에 반영해야 한다.

*출처: [Shaik SCD Gene Therapy Systematic Review European Journal of Haematology 2026](https://consensus.app/papers/details/f71effec863b55a39d2a9333578ff946/), [Oo FDA Gene Therapy Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Iglesias-López CGT Quality Regulatory Therapeutic Innovation Regulatory Science 2026](https://consensus.app/papers/details/49b52f00e1d45031af864f85aeb08f46/)*

*#FDA #GeneTherapy #Shaik #EuropeanJournalofHaematology #SCD #SystematicReview #9Programs #148Patients #DeliveryFeasibility #ExaCel #LovoCel #VF12 #OOE #TransfusionIndependence #Oo #JClinicalPharmacology #44CGTApprovals #PlatformAligned #AIAnalytics #IglesiasLópez #TherapeuticInnovation #ManufacturingComparability #PotencyAssay #Specifications #Stability #ContextualizingDay #RegulatoryContext #ClinicalContext #BiomedicalAI #DailyReport*

---

### Post 7: Spatial Transcriptomics — Spatial Ecotypes 9 SEs + GraphTME CD8 F1 0.83 + Immune Exclusion: Contextualizing

🗺️ **[Spatial Transcriptomics] Zhang et al.로 spatial ecotypes framework: 10M+ cells에서 9개 conserved spatial ecotypes(SEs) + DNA methylation profiling으로 SE 구분 + cfDNA deep learning으로 immunotherapy response 예측 + melanoma near 100명 cfDNA validation(Nature 2026) + Jeong et al.로 GraphTME: CD8+ T cells spatial ligand-receptor graph로 anti-PD-1 response prediction + F1 0.83 + MERFISH validation + NSCLC patients(NPJ Systems Biology 2026) + Zhao et al.로 spatial immune exclusion + SNHG6-BIRC5 axis lung adenocarcinoma + pan-cancer XGBoost model AUC 0.771 + immunotherapy response(Cancer Immunology Immunotherapy 2026): spatial transcriptomics Contextualizing(문맥화) 동시 확인**

Spatial transcriptomics의 **spatial ecotypes 9 SEs + GraphTME + immune exclusion mechanism(Contextualizing)**이 출처에서 동시에 확인된다[14][15][16].

**Spatial Ecotypes 9 SEs: 10M+ Cells + cfDNA Deep Learning[14]**
Wubing Zhang et al.(Nature 2026)의 연구는 spatial ecotypes(SEs) framework를 제시한다[14]. **10M+ cells**: diverse human carcinomas + melanomas에서. **9개 conserved SEs**: broad conservation across cancer types. **각 SE 고유 biology**: geospatial features + clinical outcome associations. ** immunotherapy response 연관**: 일부 SEs가 immunotherapy response와 연관. **DNA methylation profiling**: SE 구분 가능. **cfDNA deep learning**: plasma cell-free DNA에서 SE levels recoverable. **Melanoma near 100명 cfDNA validation**: immunotherapy response와 striking associations. ** liquid biopsy potential**: solid + liquid TME profiling 통합 가능. 핵심: spatial ecotypes 9 SEs 10M+ cells + cfDNA deep learning으로 immunotherapy response 예측 —液体生検 문맥화(Contextualizing).

**GraphTME: CD8+ T Cells Spatial Graph + Anti-PD-1 F1 0.83[15]**
Hoyeon Jeong et al.(NPJ Systems Biology 2026)의 연구는 GraphTME를 제시한다[15]. **Spatial ligand-receptor graph**: pathway-specific signaling을 multi-relational directed graph로 모델링. **Edge weights**: spatial distance에 반비례. **CD8+ T cells**: NSCLC patients에서 ICI-treated. **anti-PD-1 response prediction**: F1 **0.83** 초과. **MERFISH validation**: NSCLC patients clinical responses. **Responding CD8+ T cells**: higher abundance + prominent directional signalling towards tumor cells. **Antitumor activity genes**: responding cells에서 발현. 핵심: GraphTME CD8+ T cells spatial graph + anti-PD-1 F1 0.83 — 공간 면역 예측 문맥화(Contextualizing).

**Spatial Immune Exclusion: SNHG6-BIRC5 Axis + XGBoost AUC 0.771[16]**
Hong-Ying Zhao et al.(Cancer Immunology, Immunotherapy 2026)의 연구는 spatial immune exclusion mechanism을 제시한다[16]. **SNHG6-BIRC5 axis**: lung adenocarcinoma에서 immune-cold phenotype driver. **공간적 위치**: tumor nests에 localized. **T-cell infiltration negative correlation**: 면역 침윤 음성 연관. **27개 암종 통합 분석**: multi-omics framework. **XGBoost model**: 14개 regulatory features로 AUC **0.771**. **Chemotherapy sensitivity correlation**: Vinblastine 등. **PD-L1보다 우수한 예측력**: immunotherapy stratification에서. 핵심: SNHG6-BIRC5 spatial immune exclusion + XGBoost AUC 0.771 — 면역배제 메커니즘 문맥화(Contextualizing).

**Spatial Ecotypes vs GraphTME vs Immune Exclusion Differential**: Spatial ecotypes(Zhang)는 9개 conserved SEs로 보편적 TME 조직 단위를, GraphTME(Jeong)는 CD8+ T cells ligand-receptor spatial graph로 anti-PD-1 response를, Immune exclusion(Zhao)는 SNHG6-BIRC5 axis로 immune-cold phenotype 메커니즘을 제시한다. 동일 biomarker 영역이지만 framework/예측/메커니즘으로 차별화된다.

**10월 10일 Leveraging(Li Niche_4/Niche_11 + Zhang CosMx SCLC PIHs-1 + Li HiST) vs 오늘의 차별점**: 10/10이 **Li Cell Reports Medicine**으로 Niche_4/Niche_11 differential을, **Zhang Cell Reports Medicine**으로 SCLC CosMx 600K+ cells를, **Li Advanced Science**으로 HiST histology→spatial GEPs를 제시했다면, 오늘은 **Zhang Nature**으로 **9개 conserved spatial ecotypes 10M+ cells + DNA methylation + cfDNA deep learning**이라는 새로운 framework(液体生検 문맥化)를, **Jeong NPJ Systems Biology**으로 **CD8+ T cells spatial graph + MERFISH + F1 0.83**이라는 새로운 예측 도구(공간 면역 문맥화)를, **Zhao Cancer Immunology**으로 **SNHG6-BIRC5 axis immune exclusion + pan-cancer XGBoost AUC 0.771**이라는 새로운 메커니즘(면역배제 문맥화)를 동시에 제시한다. Leveraging(10/10) → spatial ecotypes framework + GraphTME + immune exclusion mechanism Contextualizing(10/11).

실무 함의: 면역종양학팀에서 Zhang et al.의 spatial ecotypes cfDNA approach를 liquid biopsy integration strategy에 적용해야 한다.

*출처: [Zhang Spatial Ecotypes Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Jeong GraphTME NPJ Systems Biology 2026](https://consensus.app/papers/details/fb21e8a3a3cc50eba50bc796e658fc7a/), [Zhao Spatial Immune Exclusion Cancer Immunology Immunotherapy 2026](https://consensus.app/papers/details/b593f440372a598586695c7975103814/)*

*#SpatialTranscriptomics #Zhang #SpatialEcotypes #Nature #10MillionCells #9SEs #Conservation #DNA methylation #cfDNA #DeepLearning #Immunotherapy #Melanoma #LiquidBiopsy #Jeong #GraphTME #NPJSystemsBiology #CD8 #Tcells #PD1 #F1Score #MERFISH #NSCLC #LigandReceptor #SpatialGraph #Zhao #CancerImmunology #SNHG6 #BIRC5 #ImmuneExclusion #LungAdenocarcinoma #XGBoost #AUC #PanCancer #ContextualizingDay #LiquidBiopsy #SpatialFramework #ImmunotherapyPrediction #BiomedicalAI #DailyReport*

---

### Post 8: 오늘의 요약 — Contextualizing(문맥화) Day 핵심 정리

🧬 **오늘 6개 영역 핵심 요약:**

10/11(Contextualizing)의 핵심: Leveraging(10/10)된 기술들이 **축적된 임상 데이터와 제도적 체계를 실제 환자 치료 맥락에 위치시키는 문맥화(Contextualizing)의 단계로 진입하며, cfDNA liquid biopsy + kidney atlas + HAE 치료 가능성 gibi 새로운 적용 영역에서 기술의 문맥화를 실현하는 날**이었다.

**1. Lonvoguran Ziclumeran HAE Phase 3 -87% Attack Rate(Cohn NEJM 2026)**: Intellia in vivo CRISPR single dose 50mg + 2:1 무작위배정 80명 + -87% monthly attack rate + median 7.5개월 follow-up + 무중대 이상 반응 없음 — Casgevy 이후 가장 중요한 CRISPR 임상 결과[1].

**2. SCD Gene Therapy 9 Programs 148 Patients Systematic Review(Shaik European Journal of Haematology 2026)**: 9개 프로그램 lentiviral/shmiR/Cas9/Cas12a/base editing + exa-cel VF12 96.7% + lovo-cel VOE 100% + delivery feasibility가 핵심 과제 — 규제-임상 통합 문맥화[2].

**3. Preclinical AI Pipeline Comprehensive Review 2020-2026(Cai Pharmaceuticals 2026)**: drug-target interaction + structure + de novo + virtual screening + ADMET + multimodal AI + digital twins + closed-loop automation — 적용 영역 체계화[3].

**4. AlphaFold Disease/Vaccine/Design Applications(Kinde Results in Engineering 2026)**: disease mechanisms + diagnostic markers + drug repurposing + vaccine design + hybrid methods로 dynamics 한계 극복 — 적용 확대 문맥화[6].

**5. Kidney Multimodal Atlas 119,744 Nuclei/Cells + scOMM(Acera-Mateos Genome Biology 2026)**: 19 donors + scOMM tool + Thick Ascending Limb/Norn/WFDC2 newly identified + horizontal/vertical integration — 장기 특이적 문맥화[9].

**6. Spatial Ecotypes 9 SEs 10M+ Cells + cfDNA Deep Learning(Zhang Nature 2026)**: 9개 conserved SEs + DNA methylation + melanoma near 100명 cfDNA validation + immunotherapy response 예측; GraphTME CD8+ F1 0.83(Jeong NPJ 2026) + SNHG6-BIRC5 immune exclusion XGBoost AUC 0.771(Zhao CII 2026) —液体生検 문맥화[14][15][16].

10월 12일 전망: Contextualizing된 기술들의 실제 환자 치료 적용과 cfDNA liquid biopsy prospective validation이 핵심 변수. 특히 Lonvoguran ziclumeran의 추가 적응증 확대, spatial ecotypes의 추가 암종 적용, kidney atlas의 다른 장기 atlas developmentへの적용이 관전이다.

Contextualizing 다음은 **Synthesizing(종합)**이다. 오늘의 6개 전선이 제시하는 공통 질문: 문맥화된 기술들이 각 분야主流 체계에서 어떤 방식으로 종합(Synthesizing)되어야 하는가. 이 질문이 내일 이후 각 전선의 핵심 과제가 된다.

*출처: [Cohn Lonvoguran Ziclumeran NEJM 2026](https://consensus.app/papers/details/014f88be1af55665a357eb28a20d5cbc/), [Shaik SCD Systematic Review European Journal of Haematology 2026](https://consensus.app/papers/details/f71effec863b55a39d2a9333578ff946/), [Zhang Spatial Ecotypes Nature 2026](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/), [Acera-Mateos Kidney Atlas Genome Biology 2026](https://consensus.app/papers/details/3e310c088a7f538a9cc7e8498109cde7/), [Kinde Harnessing AlphaFold Results in Engineering 2026](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/), [Jeong GraphTME NPJ Systems Biology 2026](https://consensus.app/papers/details/fb21e8a3a3cc50eba50bc796e658fc7a/), [Bahrami Compositional Foundation Models Cell Systems 2026](https://consensus.app/papers/details/dc130e77f84657098171472264ad3d6f/), [Cai From Algorithms to Assets Pharmaceuticals 2026](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/), [Zhao Spatial Immune Exclusion Cancer Immunology Immunotherapy 2026](https://consensus.app/papers/details/b593f440372a598586695c7975103814/), [Mao AI Drug Discovery Frontiers in Pharmacology 2026](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/), [Seyhan AI Drug Discovery Critical Reviews Oncology Hematology 2026](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/), [Singh AlphaFold Data Gap Current Opinion Structural Biology 2026](https://consensus.app/papers/details/81a3128ae1615cfeb1b6544d3ad2f1b/), [Feldman AlphaFold3 Adversarial Mutations Computational Structural Biotechnology Journal 2026](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/), [Ji CAPTAIN Nature Communications 2026](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/), [Oo FDA CGT Approvals J Clinical Pharmacology 2026](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/), [Iglesias-López CGT Quality Therapeutic Innovation 2026](https://consensus.app/papers/details/49b52f00e1d45031af864f85aeb08f08f46/)*

*#ContextualizingDay #Summary #Cohn #Lonvoguran #NEJM #HAE #87Percent #Shaik #SCD #SystematicReview #9Programs #148Patients #DeliveryFeasibility #Zhang #SpatialEcotypes #Nature #9SEs #cfDNA #LiquidBiopsy #AceraMateos #Kidney #GenomeBiology #119KCells #scOMM #Kinde #AlphaFold #Vaccine #DrugRepurposing #Jeong #GraphTME #F1 #CD8 #Zhao #SNHG6 #BIRC5 #XGBoost #AUC #Bahrami #Compositional #FoundationModels #Cai #Pharmaceuticals #Preclinical #MultimodalAI #DigitalTwins #Contextualizing #ClinicalContext #RealWorldPatients #BiomedicalAI #DailyReport*

---

## Sources (1차 출처 16개 이상)

[1] [Cohn DM, et al. Lonvoguran ziclumeran for hereditary angioedema. NEJM. 2026.](https://consensus.app/papers/details/014f88be1af55665a357eb28a20d5cbc/)
[2] [Shaik M, et al. Efficacy, safety, and treatment-delivery feasibility of autologous gene therapy for sickle cell disease: a systematic review. European Journal of Haematology. 2026.](https://consensus.app/papers/details/f71effec863b55a39d2a9333578ff946/)
[3] [Cai M, et al. From algorithms to assets: a comprehensive review of AI's role in preclinical drug discovery. Pharmaceuticals. 2026.](https://consensus.app/papers/details/9db7efc33cb250c4b08b448e73fcdd17/)
[4] [Mao Z, et al. Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation. Frontiers in Pharmacology. 2026.](https://consensus.app/papers/details/ca5321af0bb656e095b6108766231764/)
[5] [Seyhan A, et al. AI in drug discovery and development. Critical Reviews in Oncology/Hematology. 2026.](https://consensus.app/papers/details/0e6b685fd2be56fb8a814115873a73d5/)
[6] [Kinde M, et al. Harnessing AlphaFold: applications in disease understanding, drug discovery, and vaccine design. Results in Engineering. 2026.](https://consensus.app/papers/details/f459a7af7e615e27bfe6bd6e14625fea/)
[7] [Singh S, et al. More protein-ligand data is needed for AlphaFold-like models to enable drug discovery. Current Opinion in Structural Biology. 2026.](https://consensus.app/papers/details/81a3128ae1615cfeb1b6544d3ad2f1b/)
[8] [Feldman J, et al. Adversarial sequence mutations in AlphaFold and ESMFold reveal nonphysical structural invariance. Computational and Structural Biotechnology Journal. 2026.](https://consensus.app/papers/details/68f35194db525fb68a7bc8c10546001b/)
[9] [Acera-Mateos M, et al. Systematic evaluation of single-cell multimodal data integration enhances cell type resolution. Genome Biology. 2026.](https://consensus.app/papers/details/3e310c088a7f538a9cc7e8498109cde7/)
[10] [Ji BY, et al. CAPTAIN: a multimodal foundation model pretrained on co-assayed single-cell RNA and protein. Nature Communications. 2026.](https://consensus.app/papers/details/40361e55d4815c1dae3d5f6a95d4468a/)
[11] [Bahrami M, et al. From modality-specific to compositional foundation models for cell biology. Cell Systems. 2026.](https://consensus.app/papers/details/dc130e77f84657098171472264ad3d6f/)
[12] [Oo C, et al. FDA gene therapy approvals (1998–2025): current status, regulatory evolution, and future directions. J Clinical Pharmacology. 2026.](https://consensus.app/papers/details/181658e93c825ea581a0664845a98d12/)
[13] [Iglesias-López C, et al. Outlook of cell gene therapies development and approval from quality and regulatory perspective. Therapeutic Innovation & Regulatory Science. 2026.](https://consensus.app/papers/details/49b52f00e1d45031af864f85aeb08f46/)
[14] [Zhang W, et al. Non-invasive profiling of the tumour microenvironment with spatial ecotypes. Nature. 2026.](https://consensus.app/papers/details/b1d6ae0b47be530d8298e2eb72eff187/)
[15] [Jeong H, et al. GraphTME: graph-based framework for predicting immunotherapy response. NPJ Systems Biology and Applications. 2026.](https://consensus.app/papers/details/fb21e8a3a3cc50eba50bc796e658fc7a/)
[16] [Zhao HY, et al. Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion. Cancer Immunology, Immunotherapy. 2026.](https://consensus.app/papers/details/b593f440372a598586695c7975103814/)